DUBLIN, Nov. 16, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/vpd28c/global_asset) has announced the addition of the "Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2015" report to their offering.
The Global Asset Purchase Deals in Pharma, Biotech and Diagnostics 2010-2015 report provides comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter asset purchase deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all asset purchase deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in asset purchase dealmaking
Chapter 3 - Overview of asset purchase deal structure
Chapter 4 - Leading asset purchase deals
Chapter 5 - Big pharma asset purchase deals
Chapter 6 - Big biotech company asset purchase deals
Chapter 7 - Asset purchase contracts directory
For more information visit http://www.researchandmarkets.com/research/vpd28c/global_asset
Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets